MAM
GYRE icon

Marquette Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Marquette Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-866
Closed -$41K – 245
2020
Q4 		$41K Hold
866
– – 0.01% 168
2020
Q3 		$28K Hold
866
– – 0.01% 166
2020
Q2 		$38K Sell
866
-732
-46% -$34.4K 0.01% 167
2020
Q1 		$52K Buy
+1,598
New +$73.4K 0.02% 147

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Marquette Asset Management's GYRE Position: Q1 2021 in Review

Marquette Asset Management sold out of Gyre Therapeutics (GYRE) in Q1 2021, closing a stake of 866 shares — an estimated $41K sold.

Marquette Asset Management first reported a position in GYRE in Q1 2020 and held it in 4 quarters. The position peaked at $52K in Q1 2020. 89 funds tracked by Wall St. Rank hold GYRE as of Q1 2021.

  • Marquette Asset Management reported no remaining Gyre Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marquette Asset Management sold 866 Gyre Therapeutics shares in Q1 2021, an estimated $41K.
  • Marquette Asset Management first reported a position in Gyre Therapeutics in Q1 2020 and held it in 4 quarters.
  • Marquette Asset Management's Gyre Therapeutics position peaked at $52K in Q1 2020.
  • 89 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2021.

Based on Marquette Asset Management's 13F filing for Q1 2021, filed 23 Apr 2021.